Skip to main content
Premium Trial:

Request an Annual Quote

Celera Delays 10-K Filing, Postpones Conference Call

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Celera today said that it will file an extension to delay filing its Form 10-K with the US Securities and Exchange Commission, and it has postponed its fourth-quarter and fiscal-year 2010 conference call, which was scheduled for later today.

The Alameda, Calif.-based molecular diagnostics firm said that it will seek a 15-day calendar extension to file the annual report. The delay has been caused by an analysis of certain accounting issues that impact bad debt expense, primarily in its financial statements for 2008 and 2009.

The firm said these bad debt expenses include the impact of applying FASB ASC Topic 954, Health Care Entities — accounting standards that apply specifically health care firms. Celera said application of this standard will result in certain costs that were included in selling, general, and administrative expenses being reflected as a reduction in its revenues.

Celera added, however, that the application of this standard will not have any significant impact on its financial statements for the year ended Dec. 25, 2010, and it doesn't expect any impact on its 2010 net loss as a result of these issues.

As a result of the delay, Celera said that it has postponed its Q4 and FY 2010 earnings release and conference call until it files its Form 10-K.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.